Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Matthew J Maurer, Jean-Philippe Jais, Hervé Ghesquières, Thomas E Witzig, Fangxin Hong, Corinne Haioun, Carrie A Thompson, Catherine Thieblemont, Ivana N Micallef, Luis F Porrata, Vincent Ribrag, Gregorz S Nowakowski, Olivier Casasnovas, Serge Bologna, Franck Morschhauser, Vicki A Morrison, Bruce A Peterson, William R Macon, Christiane Copie-Bergman, Andrew L Feldman, Sergei I Syrbu, Paul J Kurtin, Randy D Gascoyne, Hailun Li, Cristine Allmer, Brad S Kahl, Stephen M Ansell, Susan L Slager, Brian K Link, Gilles Salles, Thomas M Habermann, Hervé Tilly, James R Cerhan
We recently defined event-free survival at 24 months (EFS24) as a clinically relevant outcome for patients with DLBCL. Patients who fail EFS24 have very poor overall survival, while those who achieve EFS24 have a subsequent overall survival equivalent to that of the age- and sex-matched general population. Here, we develop and validate a clinical risk calculator (IPI24) for EFS24. Model building was performed on a discovery dataset of 1,348 patients with DLBCL and treated with anthracycline-based immunochemotherapy...
February 2016: American Journal of Hematology
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
